Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
about
Association of Common Variants in MMPs with Periodontitis RiskInfluence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPDPersistence of oxidant and protease burden in the airways after smoking cessation.Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study.The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema.Concomitant elevations of MMP-9, NGAL, proMMP-9/NGAL and neutrophil elastase in serum of smokers with chronic obstructive pulmonary disease.FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure.Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstructionProtective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 productionCigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation?Physiology and pathophysiology of matrix metalloproteases.Chemokine expression by small sputum macrophages in COPD.Elevated Matrix Metalloproteinase Levels in Bronchi Infected with Periodontopathogenic BacteriaSpecific IgA and metalloproteinase activity in bronchial secretions from stable chronic obstructive pulmonary disease patients colonized by Haemophilus influenzaeIncreased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema.Association of circulating levels of MMP-8 with mortality from respiratory disease in patients with rheumatoid arthritis.Modeling the influence of vitamin D deficiency on cigarette smoke-induced emphysema.Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity.Distinct emphysema subtypes defined by quantitative CT analysis are associated with specific pulmonary matrix metalloproteinases.STAT3 modulates cigarette smoke-induced inflammation and protease expressionSIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD.Variability in proteinase-antiproteinase balance, nutritional status, and quality of life in stable chronic obstructive pulmonary disease due to tobacco and nontobacco etiology.Pharmacological and genetic reappraisals of protease and oxidative stress pathways in a mouse model of obstructive lung diseases.Correlation of matrix metalloproteinase-2 and -9 expression with recurrences in primary spontaneous pneumothorax patients.The development of hyperbaric oxygen therapy for skin rejuvenation and treatment of photoaging.Platelet distribution width as a prognostic factor in patients with COPD - pilot study.Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice.Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease
P2860
Q26748555-BBF855FB-6258-4363-9E34-8FA07E199D39Q28396982-087D9F83-67A7-476C-B0B3-38956DB0033FQ33453893-F7BA1D49-E7DF-46E1-A571-28DF79DFBAB1Q33540363-B643EA77-21A2-4588-8EE0-4635078D3725Q33740494-25A509C9-188C-47F1-893D-55C1E030B790Q33844617-225B8567-4B0F-4419-B23B-825B0002A3E8Q33863052-29CBEA9E-5116-4B12-B7E3-F89F72619AB3Q33876864-5A213B45-4FF8-45BA-81D3-48757E5178C4Q33898616-1D03B1D6-712D-4E15-8A71-FBF0413B4A9EQ34576797-F8E1E0CE-660E-41FE-BFB7-068B16AFFAA3Q35007715-806F2CD4-4BD9-4EE0-8ED3-E3030AD948F8Q35136709-FFD88FE0-C463-4257-808F-EADC0A868D6BQ35866106-404FCA70-3995-4483-8276-EACD9F26454BQ36539205-4782D916-CFF3-4E61-8367-747A570217A5Q36618438-BB3F59EA-27C4-43B6-AEED-8AA0D376902CQ36633139-733E82FB-EBEF-4777-B3DA-9D2EF48F21EBQ36920859-A3F233B8-4E94-4FB2-8AC1-1B2FC52E2984Q36961473-1403C53B-F172-4BB4-A0CC-A88A518C6459Q37129533-13A7006F-6ABC-4EB4-9820-4BD60A318831Q37208237-6E8A2E38-C557-43CF-B170-A423B4DDBCEEQ37342209-8784863E-F7AE-44B4-AC40-0D4F57785392Q37419622-6D5B3C53-18EE-49DE-B1D5-99DFD59EA5DBQ37508534-D7D68AB6-7C07-4C31-B234-E3F2BFBB182FQ37581268-64F9C4A9-EACD-46C2-B21B-96BC11494721Q37688420-5FE53A02-F36A-4004-9F3F-F431DE5B730CQ38621357-3FE1A5B6-14D4-4065-AE1B-733EE38F1A14Q52726398-55DDEF8D-FCCE-4DAB-854A-30CCFA34889EQ57167213-9F85C65A-5CB6-4D89-A1F8-D4DC3A226D2F
P2860
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@en
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@nl
type
label
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@en
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@nl
prefLabel
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@en
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@nl
P2093
P2860
P1476
Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD.
@en
P2093
Anssi Sovijärvi
Guy G Brusselle
Helen Ilumets
Ingel Demedts
Marjukka Myllärniemi
Paula Rytilä
Timo Sorsa
Vuokko L Kinnula
P2860
P304
P407
P577
2007-01-01T00:00:00Z